2 recruiting, 1 terminated. 1 Early Phase 1, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Early Phase 1 | 1 | Terminated 1 |
| Phase 1 | 1 | Recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
Follow Large Granular Lymphocyte Leukemia: new trials by email Literature Review of Large Granular Lymphocyte Leukemia trials Research Report on Large Granular Lymphocyte Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia zeprumetostat - Large Granular Lymphocyte Leukemia, T-LGL Leukemia | Phase 1 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 10 | 2026-10-01 | 2026-11-04 |
| JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas JAK1 Inhibitor - Lymphoma, T-Cell, NK-LGL Leukemia | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 48 | 2024-12-25 | 2025-11-18 |
| Siltuximab in Large Granular Lymphocytic Leukemia (LGLL) Siltuximab - Large Granular Lymphocyte Leukemia | Early Phase 1 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 6 | 2023-02-15 | 2026-02-05 |
Leukemia, Large Granular Lymphocytic (3) · Lymphoma, T-Cell (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1)
Hematologic Diseases (3) · Hemic and Lymphatic Diseases (3) · Immune System Diseases (3) · Immunoproliferative Disorders (3) · Leukemia (3) · Leukemia, Lymphoid (3) · Leukemia, T-Cell (3) · Lymphatic Diseases (3) · Lymphoproliferative Disorders (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Lymphoma (1) · Lymphoma, Non-Hodgkin (1)
Interleukin-6 (1) · siltuximab (1)
Institute of Hematology & Blood Diseases Hospital, China (2) · H. Lee Moffitt Cancer Center and Research Institute (1)
China (2) · United States (1)